Apr. 1, 2013
Mayo Clinic's Laboratory is now Offering Wako's DCP test
Mayo Clinic, a worldwide leader in Medical Care, is now offering Wako's DCP test (des-gamma-carboxy prothrombin). Wako's DCP test is a serum biomarker test for the risk assessment of patients with chronic liver disease for development of Hepatocellular carcinoma (HCC). The DCP test is now offered at Mayo Medical Laboratories which is a global reference laboratory that operates within Mayo Clinic's Department of Laboratory Medicine and Pathology. The addition of DCP to their test menu will complement their offering of AFP-L3 as the intended use for both tests is HCC risk assessment.
Starting March 2013, this state of the art laboratory facility will perform the DCP test three times per week. The DCP test can be ordered by using Mayo's test code 61844.
For more information, please visit Mayo's Website
Oct. 1, 2012
Wako Life Sciences, Inc. announces a medical in vitro diagnostics growth focus
Wako Life Sciences, Inc. is a newly incorporated company focused on the development, marketing, and sales of in vitro diagnostic products. As the former diagnostics division of Wako Chemicals USA, Wako Life Sciences will capitalize on its decades long reputation for high quality diagnostic reagents branded as Wako Diagnostic products. The new streamlined organization will accelerate the development of microfluidic test systems for the immunoassay and molecular diagnostic markets.
The successful use of novel microfluidics technology was first introduced with the flagship IVD test system, μTASWako® i30, launched in 2011 for the liver cancer market.
"Creating medical diagnostic value through innovative technology is the core of Wako Life Sciences", said President, Dr. Shinji Satomura. "We will leverage our research and development of microfluidic-based test systems to provide in vitro diagnostic products with rapid "sample to answer" turnaround, and superior assay sensitivity and specificity".
Wako Life Sciences, Inc. is headquartered in Mountain View, CA and has R&D facilities and commercial operations in Mountain View and Richmond, VA.
Wako Life Sciences, Inc. is a wholly owned subsidiary of Wako Pure Chemical Industries, Ltd.
Contact: Elizabeth Bouma, Wako Diagnostics, 650-210-9153
Clinical Diagnostic Reagents:
HCC Biomarkers and
Wako is a comprehensive manufacturer of Clinical Diagnostic reagents that are of the highest quality and good value to performance. Our products are the result of nearly 90 years of dedication to the field of in vitro diagnostics.
For Hepatocellular Carcinoma (HCC) Risk Assessment
Wako's AFP-L3 and DCP tests are available through major reference laboratories.
To learn how HCC biomarkers can improve surveillance of HCC: